Products
Pre-made Abrilumab benchmark antibody ( Whole mAb, anti-α4β7/Integrin alpha 4 beta 7 therapeutic antibody, Anti-LPAM‑1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-005
Pre-Made Abrilumab biosimilar, Whole mAb, Anti-α4β7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM‑1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abrilumab (INN; development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.This drug was developed by MedImmune.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-005-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Abrilumab biosimilar, Whole mAb, Anti-α4β7/Integrin alpha 4 beta 7 Antibody: Anti-LPAM‑1 therapeutic antibody |
| INN Name | Abrilumab |
| Target | α4β7 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Amgen;AstraZeneca |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Crohn's disease;Ulcerative colitis |
| Development Tech | na |
<